Dr. John W. Hubbard

Check out AscellaHealth’s Q2 Specialty & Rare Pipeline Digest featuring the latest updates on recent specialty drug approvals, upcoming reviews, CGT and biosimilar pipelines. If you haven’t already, make sure to subscribe today: https://lnkd.in/epMupw4w #specialtypharmacy #pharmaceuticals #raredisease #FollowAscellaHealth 

2

Good Morning from New Jersey! It's Day One at the Nexus Conference - 21st BioPharma Clinical Trials! What a fantastic opportunity to connect with leaders and innovators in the world of clinical trials. Today, we are excited to participate in the Panel Discussion on Running Clinical Trials in Different Geographic Regions: Assessing Opportunities and Challenges, featuring Rui Rui Zhang Xiang Business Director. Stay tuned for insights and key takeaways on overcoming the complexities of global trials! #ClinicalTrials #Biopharma #PharmaInnovation

64

1 Comment

Don't miss our co-founder and Managing Partner, Jason Robart, on the Cambridge Associates podcast! "Precision oncology represents an exciting shift in cancer treatment from a one-size-fits-all approach to personalized care based on each patient’s unique cancer and molecular makeup. In this episode, we’ll explore how precision oncology is transforming the landscape of cancer care and improving outcomes at leading hospitals like St. Jude Children’s Research Hospital. We’ll discuss the latest precision diagnostic technologies enabling doctors to analyze a tumor’s molecular profile and match targeted therapies to save lives."

9

Many biopharma professionals view smaller companies as having the best flexibility and remote work options, but that doesn’t mean their larger counterparts are failing in that area. Emily K Cox at Apogee Therapeutics, S. Nicole Schaeffer at Insmed Incorporated, Jill Drury, Pharm.D.,BCOP,MBA at AbbVie and more share insights. #workplaceflexibility #biopharma #biospace https://hubs.li/Q02Z318l0

5

In the rare disease space, every launch decision counts. Transform complexity into a strategy to navigate expedited pathways, manage risk, and avoid launch delays. Hear from our experts Dr. Kapil Raina, Brian Williams, and Chris Zealey: https://lnkd.in/eYHYwDS5 #MarketAccess #MedicalAffairs #LaunchExcellence #AskHerspiegel

1

Next week, Dinesh De Alwis, PhD, Senior Vice President of Clinical Drug Development, will join Certara’s inaugural Certainty event in Philadelphia. This unique event invites industry leaders to discuss the latest innovations that will bring us closer to “certainty” in drug development.     Dinesh will join a panel discussion about the potential of model-informed drug development (MIDD) to accelerate each phase of the process. Alongside fellow panelists Lisa Hendricks of Novartis and John Davis of Regeneron, Dinesh will share how we’re leveraging MIDD to maximize efficiency and precision across the development continuum.     Learn more about the panel, which will be moderated by Karen Rowland Yeo and Mirjam Trame of Certera. https://lnkd.in/dReXZyVt    #GenerativeBiology I #GenerativeAI

131

1 Comment

IPD’s new podcast release, "Insulins: Price Cut Aftermath and Pipeline Review," discusses the effects of recent insulin price cuts by Eli Lilly, Novo Nordisk, and Sanofi, driven by the Inflation Reduction Act (IRA).   During the episode, Stephanie N. Tran, PharmD, BCPS, covers key topics, including the impact on PBM exclusion lists, changes in formulary management, the discontinuation of Novo's Levemir, and developments in the insulin pipeline, such as Novo's insulin icodec and Lilly's insulin efsitora alfa, both once-weekly basal insulins under FDA review. Listen now: https://lnkd.in/e7hzmvTZ #insulin #diabetes #IRA #drugpricing #healthcare #novonordisk #elililly #sanofi

130

1 Comment

Thoughts on this? >> Northwell debuts gene therapy with $2.8M price tag for patients - Crain's New York Business >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #competitivemarketing #healthcare #biotech

1

𝐀𝐒𝐇 𝟐𝟎𝟐𝟒: Nurix Therapeutics CEO Arthur T. Sands, M.D., Ph.D. talks BTK degradation vs inhibition and the company's broader pipeline of degraders. He discusses Nurix's clinical data set that was presented at #ASH24. Plus, the company's pipeline, including in the autoimmune space, and degrader-antibody conjugates. Full video: https://lnkd.in/gU5gsPzW BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

96

1 Comment

#ICYMI: Nurix’s President and CEO, Arthur T. Sands, M.D., Ph.D., caught up with Brad Loncar of BiotechTV at #ASH2024 to discuss new clinical data from Nurix’s BTK degrader NX-5948 and what’s next for Nurix as we advance our pipeline of targeted protein modulation therapeutics. Watch the full interview here: https://lnkd.in/gU5gsPzW

5

We’re excited to announce that Maria I. Florez, Senior Consultant at Tufts Center for the Study of Drug Development, will be chairing the upcoming PCTO Summit in Boston! 🎉 Don’t miss this opportunity to gain insights from industry leaders and connect with professionals advancing clinical research! 🌟 #PrecisionEvolutionGlobal #Events #Summits #Conferences #Oncology #ClinicalTrials #BiopharmaLeadership #InnovationInTrials #LifeSciences #FutureOfClinicalResearch

7

https://conta.cc/3VYfeJm Sanofi has decided to shut down Kiadis Pharma N.V., a biotech firm specializing in natural killer (NK) cell therapies, just three and a half years after its acquisition for $357 million. The termination was related to a clinical trial for SAR445419, an off-the-shelf NK cell therapy for R/R AML. Similarly, Genentech, a Roche subsidiary, has terminated a $3 billion partnership with Adaptimmune. Adaptimmune remains focused on advancing its late-stage autologous pipeline, particularly its afami-cel therapy for advanced synovial sarcoma. Despite an intensifying geopolitical headwind, a small group of China biotech insiders have found out a success formula that leverages the booming China biotech innovations to achieve industry-leading success. In a Fierce Biotech article, some insiders, including our editor Leon Tang, share their experiences and advice on how to leverage Chinese innovations. Our editor Leon Tang proposes a provocative idea: Chinese innovative asset + US clinical development + Global fundraising and deal-making = success.

1

📢 Introducing one of our many #PanelDiscussions during the 2 day #PDDPSUMMIT at the Hilton Boston Park Plaza Email us at [email protected] to learn more! #DrugDiscovery #Preclinical #Antibodies #DrugDevelopment #AI #ML #MedTech #Biopharma #Pharma #Biotech #SmallMolecules #Biologics #LifeScienes #Medicine #Scientists #LifeScience #LargeMolecules

8

The flip side of this is also interesting. What are autologous therapy developers looking to improve to avoid beng outcompeted? We are hearing a lot of interest in understanding what is possible in terms of compressed or "fast" autologous manufacturing. There seems to be particular interest in the cell activation and expansion phases although there are many areas that can be optimised to improve vein-to-vein time. There's a nice summary of some these trends in this GEN news article https://lnkd.in/eqjnMzGG

3

The collaboration between Virpax Pharmaceuticals Inc. (Nasdaq:VRPX) Pharmaceuticals and the National Center for Advancing Translational Sciences (NCATS) heralds a significant advancement in pain management research. Focused on the development of NES100, an intranasal peptide targeting acute and chronic non-cancer pain, this partnership utilizes innovative nanotechnology to enhance the delivery of enkephalin to the brain. By leveraging Molecular Envelope Technology (MET) and a specialized device, NES100 aims to provide analgesic effects without the adverse events commonly associated with opioids. This extended collaboration underscores the shift towards non-opioid alternatives for pain management, crucial in addressing the opioid crisis. The research aligns with the NIH’s HEAL initiative, emphasizing the national commitment to combat opioid addiction. The potential of NES100 lies in offering a non-addictive pain treatment, potentially transforming pain therapy and improving outcomes for individuals with chronic pain conditions. NES100's development presents a promising avenue for pain management, offering a safer alternative to traditional opioids. If proven effective in clinical trials, NES100 could emerge as a valuable tool for patients seeking pain relief. The intranasal delivery method not only enhances convenience but also holds the promise of improved patient adherence and treatment efficacy. 𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞: https://lnkd.in/dwMpJZf8 Gerald W. Bruce Matt Barnes

2